Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.
Explore how type 2 inflammation drives the production of IgE in severe asthma
Explore how type 2 inflammation drives the production of FeNO in severe asthma
Explore how type 2 inflammation drives the production of eosinophils in severe asthma.

Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses emerging evidence that therapy-free disease control may be possible in atopic dermatitis, citing pediatric dupilumab data showing that a subset of patients-maintained remission after treatment discontinuation.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025

In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.

Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.

Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.